Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.

Raymond U OsarogiagbonDiana Merino Vega Lola A Fashoyin-Aje Suparna WedamGwynn IsonSol AtienzaPeter De PorreTithi Biswas Jamie N Holloway David S HongMadison M WempeRichard L SchilskyEdward S KimJames L Wade

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Clinical trial sponsors and regulators should thoughtfully reexamine the use of prior therapy exposure as selection criteria to maximize clinical trial participation.See related commentary by Giantonio, p. 2369.

Keyphrases

clinical trial
phase ii
open label
double blind
study protocol
phase iii
papillary thyroid
physical activity
transcription factor
squamous cell carcinoma
randomized controlled trial
stem cells
squamous cell
bone marrow
mesenchymal stem cells
drug induced